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The human body physiologically requires gastric acid for efﬁcient absorption of calcium through the
small intestine. A proton-pump inhibitor reduces acidity in the stomach, and impairs the absorption of
food and therapeutic preparations of calcium salts in the small intestine. Hypomagnesemia is a rare
adverse effect of a proton-pump inhibitor. We report a 64-year-old man with a malignant neoplasm of
the hypopharynx. After a total pharyngolaryngectomy, bilateral selective neck dissection (levels II, III, and
IV), and right thyroidectomy, he developed hypocalcemia, hypomagnesemia, and hypoparathyroidism.
After the administration of calcium and magnesium supplements, the patient's serum calcium and
magnesium levels were still abnormal. The patient was later found to be taking an oral proton-pump
inhibitor (esomeprazole) to treat a peptic ulcer. After discontinuing the oral proton-pump inhibitor,
the patient was found to have normal serum calcium and magnesium levels under supplementation with
oral calcium and 1,25-dihydroxyvitamin D.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Proton-pump inhibitors (PPIs) have been usedwidely since their
introduction in the late 1980s because they are highly effective for
the treatment of gastric acid-related diseases [1]. PPIs act by
inhibiting the proton pump or Hþ/Kþ adenosine triphosphatase
found on gastric mucosal parietal cells, and reduce the secretion of
gastric acid [2]. Therefore, PPIs contribute to changes in the gastric
and intestinal pH environments, which may impact the absorption
of nutrients with some clinical consequences. The notion that PPIs
interfere with the absorption of calcium and magnesium has often
been discussed. We report a patient with a malignant neoplasm of
the hypopharynx who received a total pharyngolaryngectomy,and Metabolism, Department
Tzu Chi Medical Foundation,
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elief Tzu Chi Foundation. Publishebilateral selective neck dissection (levels II, III, and IV), and right
thyroidectomy. The patient had hypocalcemia, hypomagnesemia,
and very low levels of parathyroid hormone.
2. Case Report
A 64-year-old man with a malignant neoplasm of the hypo-
pharynx, T1N0Mx, stage I, was admitted to the otolaryngology ward
for a total pharyngolaryngectomy, bilateral selective neck dissec-
tion (levels II, III, and IV), and right thyroidectomy. On the 3rd
postoperative day, the patient developed paresthesia and muscle
cramps in the four limbs. Laboratory studies revealed hypocalcemia
(serum calcium: 1.35 mmol/L), hypomagnesemia (serum magne-
sium: 1.3 mg/dL), and very low levels of parathyroid hormone
(serum intact parathyroid hormone: 1.5 pg/mL). Primary hypo-
parathyroidism was diagnosed. The patient's symptoms, as well as
serum calcium and magnesium levels improved after continuous
administration of intravenous calcium gluconate and oral magne-
sium oxide. However, the patient repeatedly developed severe
hypocalcemia when shifted to oral calcium carbonate and 1,25-d by Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical course and laboratory examinations.
April 15, 2011 Prior to surgery Ca: 2.29 (2.12e2.52) mmol/L; albumin: 3.5 (3.4e5.0) g/dL
April 27, 2011 Surgery for hypopharynx cancer 1. Total pharyngolaryngectomy
2. Bilateral selective neck dissection (levels II, III, IV)
3. Right thyroidectomy
April 30, 2011 Symptoms of paresthesias and muscle cramps Ca: 1.35 mmol/L; P: 3.5 (2.5e4.9) mg/dL; Mg: 1.3 (1.8e2.4) mg/dL; albumin: 2.0 g/dL;
Na: 136 mmol/L; K: 3.5 mmol/L; i-PTH: 1.5 (14e72) pg/mL
Intravenous injection calcium gluconate Calcium gluconate (0.898 meq/mL, 5 mL/amp) 5 amp in 500 mL normal saline run 20 mL/h
(0.014 meq/mL/min)
Oral magnesium oxide Magnesium oxide 250 mg/tab 1# t.i.d.
May 5, 2011 Ca: 1.69 mmol/L; calcium gluconate intravenous injection form shift to CaCO3 (500 mg/tab)
oral form 3# q6h; calcitriol 0.25 mg/cap 1# q12 h
May 7, 2011 Intravenous injection calcium gluconate Ca: 1.39 mmol/L; calcium oral form shift to calcium gluconate intravenous injection form
May 11, 2011 Oral thyroxin TSH: 28.6 mIU/mL; free T4: 0.79 ng/dL
June 3, 2011 Ca: 1.60 mmol/L; calcium gluconate intravenous injection form shift to CaCO3 oral form
3# q4h; calcitriol 0.25 mg/cap 1# q8h
June 5, 2011 Intravenous injection calcium gluconate Ca: 1.45 mmol/L; P: 5.9 mg/dL; Mg: 3.4 mg/dL; albumin: 2.8 g/dL; Na: 135 mmol/L; K:
3.9 mmol/L
June 7, 2011 Stop esomeprazole Esomeprazole was started on Apr 29, 2011
June 10, 2011 Ca: 1.78 mmol/L; P: 4.3 mg/dL
June 17, 2011 Ca: 2.04 mmol/L; P: 6.1 mg/dL; albumin: 2.9 g/dL
Oral agents after hospital discharge Calcium citrate (950 mg/tab) 5# q8h; calcitriol 0.25 mg/cap 1# q8h; thyroxine 100
mg/tab 8#/qw
August 27, 2012 Ca: 2.2 mmol/L; P: 4.1 mg/dL; albumin: 4.0 g/dL; Na: 140 mmol/L; K: 3.7 mmol/L; TSH:
1.093 (0.25e4.0) mIU/mL; free T4: 1.266 (0.8e2.0) ng/dL
CaCO3 ¼ calcium carbonate; free T4 ¼ free thyroxine; i-PTH ¼ intact parathyroid hormone; TSH ¼ thyroid-stimulating hormone.
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found that he was taking an oral PPI (oral administration of 20 mg
esomeprazole per day) for a peptic ulcer. After discontinuation of
the oral PPI, the patient achieved normal serum calcium and
magnesium levels under supplementation with oral calcium and
1,25-dihydroxyvitamin D.3. Discussion
It is well established that calcium must be in a soluble, ionized
form to be absorbed. In normal circumstances, prior to food chyme
reaches the small intestine, gastric acid and the slightly acidic
environment help in the dissolution of calcium, leading to the
formation of calcium ions that can be absorbed. PPIs are powerful
gastric acid suppressors that may reduce the bioavailability of
calcium for gastric and intestinal absorption. Gastric acid is
necessary to facilitate effective absorption of calcium in the intes-
tine. In 1967, Ivanovich et al [3] showed that calcium was not
absorbed from carbonate when basal stomach acid secretion was
zero. A study by Recker [4] in 1985 found that calcium absorption
from carbonate is impaired in achlorhydria. The inhibition of gastric
acid secretion by dietary omeprazole (a PPI) in male Wister rats
decreased calcium absorption from calcium carbonate. Chonan et al
[5] reported that dietary lactic acid prevented calcium absorption in
rats fed with omeprazole.
O'Connell et al [6] measured intestinal calcium absorption in
humans using a radiolabeled calcium isotope. They reported that
women who were aged 65 years and older and taking omeprazole
at a dose of 20 mg once a day for 7 days had a signiﬁcant reduction
in the absorption of calcium carbonate taken under fasting condi-
tions. This study showed that omeprazole therapy decreased cal-
cium absorption from calcium carbonate signiﬁcantly when
ingested by elderly women after an overnight fast and on an empty
stomach [6]. Calcium carbonate and calcium citrate are the most
common calcium supplements. Calcium carbonate should be taken
with a meal to ensure optimal absorption. Calcium citrate can be
takenwithout food, and is the supplement of choice for individuals
with achlorhydria and those who are taking histamine-2 blockers
or PPIs [7].Hypomagnesemia is a rare but serious adverse effect of PPI. The
ﬁrst case of PPI-associated hypomagnesemia was reported in 2006
[8]. Two patients presented with carpopedal spasms in association
with severe hypomagnesemic and hypocalcemic hypoparathyroid-
ismwhen they were treated with PPIs [8]. In the United States Food
and Drug Administration database, only 1% of the 66,102 patients
who experienced various adverse effects due to PPI use presented
with hypomagnesemia [9]. Patients with hypomagnesemia often
develop secondary hypocalcemia and hypokalemia. According to
the United States Food and Drug Administration data, there is a
strong association between PPI-associated hypomagnesemia and
hypocalcemia. More than 60% of the patients who had hypomag-
nesemia also had hypocalcemia [9]. Our patient also developed
hypomagnesemic and hypocalcemic hypoparathyroidism associ-
ated with the use of oral PPIs. After discontinuing the oral PPI, the
levels of calcium andmagnesium in the serumnormalized (Table 1).
In conclusion, we suggest that serum magnesium and calcium
levels be checked regularly in patients with hypoparathyroidism
who take PPIs or histamine-2 blockers. Calcium carbonate should
be taken with a meal for its effective absorption. Calcium citrate,
which can be ingested without food, is the supplement of choice for
individuals who are taking PPIs or histamine-2 blockers.
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